Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.
Garrett, Jennifer K
Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. [electronic resource] - The Journal of allergy and clinical immunology Jan 2004 - 115-9 p. digital
Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
0091-6749
10.1016/j.jaci.2003.10.049 doi
Adolescent
Adult
Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Humanized
Drug Therapy, Combination
Eosinophils--immunology
Female
Glucocorticoids--therapeutic use
Humans
Hypereosinophilic Syndrome--drug therapy
Interleukin-5--immunology
Leukocyte Count
Male
Middle Aged
Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. [electronic resource] - The Journal of allergy and clinical immunology Jan 2004 - 115-9 p. digital
Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
0091-6749
10.1016/j.jaci.2003.10.049 doi
Adolescent
Adult
Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Humanized
Drug Therapy, Combination
Eosinophils--immunology
Female
Glucocorticoids--therapeutic use
Humans
Hypereosinophilic Syndrome--drug therapy
Interleukin-5--immunology
Leukocyte Count
Male
Middle Aged